biostudies-literatureUnknown12Zhu H<h4>Background</h4>Several studies have suggested that anti-silencing function 1 B (ASF1B) can serve as a good potential marker for predicting tumor prognosis. But the values of ASF1B in gliomas have not been elucidated and further confirmation is needed.<h4>Methods</h4>Transcriptomic and clinical data were downloaded from The Cancer Genome Atlas database (TCGA), genotypic tissue expression (GTEx), and the Chinese Gliomas Genome Atlas database (CGGA). Univariate and multivariate Cox regression analyses were used to investigate the link between clinical variables and ASF1B. Survival analysis was used to assess the association between ASF1B expression and overall survival (OS). The relationship between ASF1B expression and OS was studied using survival analysis. To investigate the probable fFrontiers in oncology912101https://www.ebi.ac.uk/biostudies/studies/S-EPMC9298524biostudies-literatureIncreased ASF1B Expression Correlates With Poor Prognosis in Patients With Gliomas.PMC9298524Pan XYu NOuyang HZhang ZTan JZhu HLi MZhao YfalseIncreased ASF1B Expression Correlates With Poor Prognosis in Patients With Gliomas.<h4>Background</h4>Several studies have suggested that anti-silencing function 1 B (ASF1B) can serve as a good potential marker for predicting tumor prognosis. But the values of ASF1B in gliomas have not been elucidated and further confirmation is needed.<h4>Methods</h4>Transcriptomic and clinical data were downloaded from The Cancer Genome Atlas database (TCGA), genotypic tissue expression (GTEx), and the Chinese Gliomas Genome Atlas database (CGGA). Univariate and multivariate Cox regression analyses were used to investigate the link between clinical variables and ASF1B. Survival analysis was used to assess the association between ASF1B expression and overall survival (OS). The relationship between ASF1B expression and OS was studied using survival analysis. To investigate the probable f2022-01-01T00:00:00Z20222025-04-21T17:28:55.807Z2025-04-21T17:28:55.807ZS-EPMC92985243587509410.3389/fonc.2022.912101